ALLO
Allogene Therapeutics, Inc.
Allogene Therapeutics (ALLO) Q2 2026 earnings
Published Aug 12, 2026
AI summary
- Revenue $5K, up from $0 a year ago.
- GAAP EPS −$0.13, up from −$0.23 a year ago.
- Allogene reported a net loss of $42.7 million for the second quarter of 2026.
- The company generated $4,640 in collaboration revenue during the quarter.
- The ALPHA3 trial for Cema-cel showed positive interim results with no serious treatment-related adverse events.
Results vs analyst consensus
Revenue
Reported
$5K
Consensus not captured before release
EPS · GAAP
Reported · GAAP diluted EPS
−$0.13
Consensus not captured before release
Prior year: −$0.23
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company is a clinical-stage biotechnology firm with minimal revenue and ongoing operating losses.
- Future financial results depend on the successful development and regulatory approval of its pipeline candidates.
Read original report
Source: Allogene Therapeutics, Inc. press release · SEC Form 8-K exhibit 99.1